Sveikatal is developing drug candidates that can treat major diseases, including
type 2 diabetes, fatty liver disease, hyperlipidemia, and cancer.
Sveikatal’s discovery and IP platform is based on more than
twenty years of cutting-edge research on vitamin A and its metabolites, developed at Cornell University and Weill Cornell Medical College (New York, USA). This program continues to be
supported by National Institutes of Health (NIH) and other organizations.
Preclinical studies have already identified promising compounds that treat four different diseases.
These drug candidates may provide novel therapies for a major classes of diseases with either no current treatments or treatments that need to be dramatically improved.